NICE no for Tyverb and Herceptin in breast cancer, Roche considers appeal
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has again said no to recommending GSK's Tyverb (lapatinib) and Roche's Herceptin (trastuzumab) for treating metastatic hormone-receptor-positive breast cancer that overexpresses HER2. Roche is thinking of appealing, while GSK is "considering its options", the companies told Scrip.